Precision Medicine and Cancer Genomics: An Industry Perspective · 0 Precision Medicine and Cancer...
Transcript of Precision Medicine and Cancer Genomics: An Industry Perspective · 0 Precision Medicine and Cancer...
0
Precision Medicine and Cancer Genomics:An Industry Perspective
David R. Cox M.D., Ph.D.Senior Vice President and Chief Scientific Officer, AQG
Pfizer Inc.
1
Bedside to Bench
Molecular Targets
Target to clinic:
Poor alignment of molecularunderstanding to clinical need
Clinical Outcome
Clinic to target:
Defined unmet clinical need
Translation from human geneticvariation, to optimized therapybased on an understanding of
biology
VS.
Human genetics links clinical outcomes of interest to the relevant biology
Human Genetics
Traditional Discovery
2
Patient Stratification
Genetic knowledge will reclassify disease based on
biological causality
Individuals will receive “group” assignments
based on this information
Selection of clinical trial participants based on
biological knowledge prior to therapeutic intervention
3
Targeting Somatic Cancer “Driver Mutations”
4
Crizotinib Target Profile
5
6
7
8
9
Shaw AT, et al. Phase 3 randomized study of crizotinib versus pemetrexed or docetaxel chemotherapy in advanced, ALK-positive
NSCLC (PROFILE 1007). Vienna, Austria: European Society for Medical Oncology; September 30, 2012. Abstract LBA1.
The study met its primary endpoint of progression-free survival(PFS): median PFS was 7.7 months with crizotinib versus 3.0months with chemotherapy, representing a 51% reduction in risk ofprogression for the ALK inhibitor (P < .0001)
Phase III PROFILE 1007 Trial- a global study conducted at more than 100sites in 20 countries. The study randomized 347 patients with ALK+, stageIIIb or IV NSCLC to crizotinib 250 mg/bid; pemetrexed 500 mg/m2; ordocetaxel 75 mg/m2 on a 21-day cycle. Median number of cycles oftreatment was 11 for crizotinib and 4 for chemotherapy.
Crizotinib superior to single agent chemotherapy in advanced, previously
treated ALK-postive, non- small cell lung cancer (NSCLC)
Recent Good News
10
Shaw AT, et al. Phase 3 randomized study of crizotinib versus pemetrexed or docetaxel chemotherapy in advanced, ALK-positive NSCLC (PROFILE1007). Vienna, Austria: European Society for Medical Oncology; September 30, 2012. Abstract LBA1.
According to independent radiologic review, crizotinib tripled theoverall response rate compared with chemotherapy: 65.3%versus 19.3%, respectively (P < .0001).
Quality of life was superior for crizotinib-treated patients, basedon patient reported outcomes regarding time to deterioration inlung cancer symptoms: median of 5.6 months with crizotinibversus 1.4 months with chemotherapy (P < .0001).
Toxicities of crizotinib were mild and manageable,
Recent Good News
11
The Bad News
With a median progression free survival of 7 months,patients will develop resistance to this targeted therapy.
Two next-generation ALK inhibitors are in phase II studies—LBK 178 and AB6 273
12
This article was published on October 1,2012, at NEJM.org. DOI: 10.1056/NEJMoa1209124
Antibody- Drug Conjugates
13
Recent Good News
Among 991 randomly assigned patients, median progression-freesurvival as assessed by independent review was 9.6 months with T-DM1 versus 6.4 months with lapatinib plus capecitabine (hazard ratiofor progression or death from any cause, 0.65; 95% confidence interval[CI], 0.55 to 0.77; P<0.001Rates of grade 3 or 4 adverse events were higher with lapatinibplus capecitabine than with T-DM1 (57% vs. 41%).
Randomly assigned patients with HER2-positive advanced breastcancer, who had previously been treated with trastuzumab and a taxane,to T-DM1 or lapatinib plus capecitabine. The primary end points wereprogression-free survival (as assessed by independent review), overallsurvival, and safety.
14
15
16
ADC Development Focus Areas
1. Design new inkers and payloads with tumor selectivity
2. Cancer target expression levels not predictive for pharmacology
3. Imporve understanding of factors affecting pharmacodynamics
and toxicity
4. Improve biodistribution- less than 0.01% of ADC injected reaches
the tumor
17
Bioconjugation Methodologies
18
Cancer Immunotherapy
19
Conclusions
Anti–PD-1 antibody produced objective responses in approximately one in four toone in five patients with non–small-cell lung cancer, melanoma, or renal-cell cancer;the adverse-event profile does not appear to preclude its use.
Preliminary data suggest a relationship between PD-L1 expression on tumor cells
and objective response.
20
Tumor PD-1L Expression is Associated with Objective Response
to PD-1 Antibody Therapy
21
PD-1 and PD-1L have overlapping but not identical binding partners
22
Committee on a Framework for Development a New Taxonomy of Disease;
National Research Council
Toward Precision Medicine:Building a Knowledge Network for Biomedical Research and a New Taxonomy of Disease
23
The pharmaceutical industry needs to engage internationalscientific and healthcare communities in a more collaborative
fashion in order to achieve the goal of improving health outcomes
A critical unmet need is access to cohorts of individuals with wellcharacterized differences in disease progression and treatment
outcomes
Money alone does not provide access to the critical scientificcollaborative relationships
Key Insights
24
BBMRI: A pan-European infrastructure for work onBiosamples and Clinical Data
Preparatory Phase
2008-2011
5 mio €
53 Participants
222 Ass. Partners
33 Countries
BBMRI: Biobanking and Biomolecular ResourcesResearch Infrastructure
Objectives:
Infra-structure and collaboration models for
working with biosamples in Europe.
Provide a European and global ethical and
legal framework for work on biosamples
Current Initiatives
BBMRI – ERIC: Legal framework for working with biosamples will be rolled out Q1 2013
BBMRI – LPC: EU F7P program to facilitate sharing of samples and data in 50 European populationbiobanks
BBMRI Expert Centers: Vehicles for collaboration on biosamples and clinical data
25
•Linking biospecimens to multiple sources ofhealthcare information, while protecting all
stakeholders
•Reconciling altruism and open collaborationwith intellectual property and profit
Major Challenges
26
•Keep the detailed clinical data and related biospecimens withthe clinicians and scientists who generated them and who
have established relationships with the study subjects and thelocal culture.
•Use public-private scientific collaborative expertise andresources to obtain the key biologic knowledge required to
address specific health outcomes.
•This key biologic knowledge can then be used by all toimprove health outcomes
Potential Solution: “Expert Centres”
27
BBMRI Expert Centres
Collaborative Research in Public and Private Sectors
Medical data
Biological samples
Knowledge
Primary
data
generation
Diagnostics
Drugs
Public
(not-for-profit)
Private
(for-profit)
Public-private
(not-for-profit)
Data
Insights
Products
ExpertiseExpertise
Funds
Common good
(donations)
Industry
(sales)
www.bbmri.eu/
28
Expert Centres as Highways forTransnational Research Collaborations
Samples
Medical
Data
Country 1
Biological
Resource
Centre
Expert
Centre
Samples
Medical
Data
Country 2
Biological
Resource
Centre
Expert
Centre
Research
Data
Samples
Medical
Data
Country 3
Biological
Resource
Centre
Expert
Centre
www.bbmri.eu/
29
June 13, 2011April 22, 2002